加载中
XTL Biopharmaceuticals Ltd. is a biopharmaceutical firm dedicated to identifying and advancing novel drug therapies for autoimmune conditions. Its primary investigational compound, hCDR1, is poised to enter Phase II trials, specifically targeting systemic lupus erythematosus and Sjogren's syndrome. The company holds a crucial licensing agreement with Yeda Research and Development Company Limited, which grants rights for the research, development, and eventual commercialization of hCDR1 across multiple therapeutic indications. Originally established in 1993 as Xenograft Technologies Ltd., the company rebranded to XTL Biopharmaceuticals Ltd. in July 1995. It operates from its headquarters in Ramat Gan, Israel.
收盘时
US$1.92
−US$0.06 · -3.03%
盘中时间采用ET。市场数据可能有所延迟。
XTL Biopharmaceuticals Ltd. is a biopharmaceutical firm dedicated to identifying and advancing novel drug therapies for autoimmune conditions. Its primary investigational compound, hCDR1, is poised to enter Phase II trials, specifically targeting systemic lupus erythematosus and Sjogren's syndrome. The company holds a crucial licensing agreement with Yeda Research and Development Company Limited, which grants rights for the research, development, and eventual commercialization of hCDR1 across multiple therapeutic indications. Originally established in 1993 as Xenograft Technologies Ltd., the company rebranded to XTL Biopharmaceuticals Ltd. in July 1995. It operates from its headquarters in Ramat Gan, Israel.
日内区间
当前US$1.92
52周区间
当前US$1.92
盘中时间采用ET。市场数据可能有所延迟。
XTL Biopharmaceuticals Ltd. is a biopharmaceutical firm dedicated to identifying and advancing novel drug therapies for autoimmune conditions. Its primary investigational compound, hCDR1, is poised to enter Phase II trials, specifically targeting systemic lupus erythematosus and Sjogren's syndrome. The company holds a crucial licensing agreement with Yeda Research and Development Company Limited, which grants rights for the research, development, and eventual commercialization of hCDR1 across multiple therapeutic indications. Originally established in 1993 as Xenograft Technologies Ltd., the company rebranded to XTL Biopharmaceuticals Ltd. in July 1995. It operates from its headquarters in Ramat Gan, Israel.
日内区间
当前US$1.92
52周区间
当前US$1.92
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | — | 45.1万 USD | — | — | — |
| 销货成本 | — | 44.8万 USD | — | 1000 USD | 1000 USD |
| 毛利 | — | 3000 USD | — | −1000 USD | −1000 USD |
| 研究与开发 | 2.8万 USD | 9.8万 USD | 3.1万 USD | 3万 USD | 3万 USD |
| 销售、一般及管理费用 | 112.9万 USD | 204.6万 USD | 73.4万 USD | 85万 USD | 100.1万 USD |
| 营业费用 | 168.8万 USD | 217.5万 USD | 76.5万 USD | 88万 USD | 103.1万 USD |
| 利息收入 | 6万 USD | 3.4万 USD | 4.1万 USD | 3.6万 USD | 8000 USD |
| 利息支出 | 7000 USD | 8.6万 USD | 3999 USD | 1.1万 USD | 2.1万 USD |
| 折旧和摊销 | — | 19.9万 USD | 1000 USD | 1000 USD | 1000 USD |
| 营业利润 | −168.8万 USD | −217.2万 USD | −76.5万 USD | −88万 USD | −103.1万 USD |
| 净利润 | −696.9万 USD | −102.7万 USD | −1782 USD | −134.8万 USD | 43.5万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
